OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis
Kaneez Fatima, Abdul Moeed, Eisha Waqar, et al.
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101816-101816
Closed Access | Times Cited: 41
Kaneez Fatima, Abdul Moeed, Eisha Waqar, et al.
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101816-101816
Closed Access | Times Cited: 41
Showing 26-50 of 41 citing articles:
Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches
Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, et al.
Metabolism (2024), pp. 156044-156044
Closed Access | Times Cited: 2
Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, et al.
Metabolism (2024), pp. 156044-156044
Closed Access | Times Cited: 2
Liver fat analysis using optimized support vector machine with support vector regression
B. Pushpa, B. Baskaran, S. Vivekanandan, et al.
Technology and Health Care (2023) Vol. 31, Iss. 3, pp. 867-886
Closed Access | Times Cited: 6
B. Pushpa, B. Baskaran, S. Vivekanandan, et al.
Technology and Health Care (2023) Vol. 31, Iss. 3, pp. 867-886
Closed Access | Times Cited: 6
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
Merve Çebi, Yusuf Yılmaz
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Merve Çebi, Yusuf Yılmaz
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
Ning Gao, Jiang Deng, Jinhai Wang, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Ning Gao, Jiang Deng, Jinhai Wang, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III
Rodrigo M. Carrillo‐Larco, Wilmer Cristobal Guzman‐Vilca, Manuel Castillo-Cara, et al.
BMJ Open (2022) Vol. 12, Iss. 11, pp. e067203-e067203
Open Access | Times Cited: 5
Rodrigo M. Carrillo‐Larco, Wilmer Cristobal Guzman‐Vilca, Manuel Castillo-Cara, et al.
BMJ Open (2022) Vol. 12, Iss. 11, pp. e067203-e067203
Open Access | Times Cited: 5
Statin Intolerance: An Overview for Clinicians
Stanisław Surma, Joanna Lewek, Peter E. Penson, et al.
Contemporary diabetes (2023), pp. 597-635
Open Access | Times Cited: 2
Stanisław Surma, Joanna Lewek, Peter E. Penson, et al.
Contemporary diabetes (2023), pp. 597-635
Open Access | Times Cited: 2
Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
Ahmed Osman, Vladimir S. Shavva, Laura Tarnawski, et al.
Journal of Internal Medicine (2024)
Closed Access
Ahmed Osman, Vladimir S. Shavva, Laura Tarnawski, et al.
Journal of Internal Medicine (2024)
Closed Access
Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment
Willy Theel, Vivian D. de Jong, Manuel Castro Cabezas, et al.
European Journal of Clinical Investigation (2024)
Open Access
Willy Theel, Vivian D. de Jong, Manuel Castro Cabezas, et al.
European Journal of Clinical Investigation (2024)
Open Access
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
Davide Misceo, Gabriele Mocciaro, Simona D’Amore, et al.
Nutrition & Metabolism (2024) Vol. 21, Iss. 1
Open Access
Davide Misceo, Gabriele Mocciaro, Simona D’Amore, et al.
Nutrition & Metabolism (2024) Vol. 21, Iss. 1
Open Access
Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study
C H Lee, Yu-Han Huang, Tzu-Ju Hsu, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 6495-6511
Open Access
C H Lee, Yu-Han Huang, Tzu-Ju Hsu, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 6495-6511
Open Access
Association of Statin Adherence With the Development of Nonalcoholic Fatty Liver Disease: A Nested Case-Control Study Using a Japanese Claims Database
Chihiro NAKAGAWA, S. Yokoyama, Kouichi Hosomi
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 6, pp. 637-645
Closed Access | Times Cited: 2
Chihiro NAKAGAWA, S. Yokoyama, Kouichi Hosomi
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 6, pp. 637-645
Closed Access | Times Cited: 2
Liver fibrosis in a comorbid patient with metabolicassociated (non-alcoholic) fatty liver disease (MAFLD-NAFLD) and cardiovascular disease
М. А. Ливзан, Т. С. Кролевец, M. I. Syrovenko
Experimental and Clinical Gastroenterology (2023), Iss. 4, pp. 133-139
Open Access
М. А. Ливзан, Т. С. Кролевец, M. I. Syrovenko
Experimental and Clinical Gastroenterology (2023), Iss. 4, pp. 133-139
Open Access
Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular complications: what do they have in common?
Ametov As, С. В. Туркина
Endocrinology News Opinions Training (2023) Vol. 12, Iss. 4, pp. 87-98
Open Access
Ametov As, С. В. Туркина
Endocrinology News Opinions Training (2023) Vol. 12, Iss. 4, pp. 87-98
Open Access
Evaluation of Coronary Artery Disease Among Patients with Non-Alcoholic Fatty Liver Diseases Using Multislice C.T.
M.D. AHMED M. OSMAN AMANY M. RASHAD, M.Sc. MAHMOUD A. MARIE
The Medical Journal of Cairo University/The Medical Journal of Cairo University (2022) Vol. 90, Iss. 3, pp. 583-591
Open Access
M.D. AHMED M. OSMAN AMANY M. RASHAD, M.Sc. MAHMOUD A. MARIE
The Medical Journal of Cairo University/The Medical Journal of Cairo University (2022) Vol. 90, Iss. 3, pp. 583-591
Open Access
Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101842-101842
Closed Access
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101842-101842
Closed Access
Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?
Abia Shahid, Huzaifa Ahmad Cheema
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101826-101826
Closed Access
Abia Shahid, Huzaifa Ahmad Cheema
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101826-101826
Closed Access
